Aldeyra Therapeutics, Inc. (ALDX)
| Market Cap | 104.05M -24.9% |
| Revenue (ttm) | n/a |
| Net Income | -27.37M |
| EPS | -0.45 |
| Shares Out | 60.32M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 383,435 |
| Open | 1.700 |
| Previous Close | 1.730 |
| Day's Range | 1.700 - 1.770 |
| 52-Week Range | 1.070 - 6.175 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | 5.50 (+218.84%) |
| Earnings Date | May 22, 2026 |
About ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ALDX stock is "Buy." The 12-month stock price target is $5.5, which is an increase of 218.84% from the latest price.
News
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 29, 2026 in Aldeyra Therapeutics, Inc. Lawsuit - ALDX
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). Shareholders who purchased shares of ALDX during...
REMINDER: Aldeyra Therapeutics, Inc. Investors With Significant Losses Must Act By May 29, 2026
NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investors of the May 29, 2026 deadline to seek the role o...
ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role
NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email...
ADLX Stockholders Have Rights – If You Lost Money Investing in Aldeyra Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (...
Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors to Contact the Firm Regarding Their Rights
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aldeyra (ALDX) To Contact Him Directly To Discuss Their Options
Shareholders who lost money in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Should Contact Wolf Haldenstein Immediately
Lead Plaintiff Deadline is May 29, 2026 NEW YORK, April 7, 2026 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP informs investors that a securities fraud class action lawsuit has been filed ...
$ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses
A securities fraud lawsuit has been filed against Aldeyra Therapeutics (Nasdaq: ALDX). Investors who lost money in ALDX should contact Block & Leviton.
Aldeyra downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra (ALDX) to Neutral from Buy with a price target of $2, down from $10, after the company received a complete response letter from
Aldeyra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 17, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Aldeyra Therapeutics (NASDAQ: ALDX). The investigation focus...
FDA issues Aldeyra CRL saying reproxalap NDA failed to demonstrate efficacy
Aldeyra (ALDX) announced receipt of a complete response letter, or CRL, from the FDA for the new drug application, or NDA, of reproxalap, an investigational drug candidate, for the treatment
How Did the FDA Shatter Investor Confidence In Aldeyra Therapeutics Stock (ALDX) Today?
Aldeyra Therapeutics stock fell hard on Tuesday after it received a CRL from the FDA.
US FDA declines to approve Aldeyra's drug for eye disorder
The U.S. Food and Drug Administration on Tuesday declined to approve Aldeyra Therapeutics' drug for a type of eye disease, the company said.
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra options imply 10.9% move in share price post-earnings
Pre-earnings options volume in Aldeyra (ALDX) is 1.6x normal with puts leading calls 10:9. Implied volatility suggests the market is anticipating a move near 10.9%, or 50c, after results are
Aldeyra Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Reproxalap is nearing a key FDA decision for dry eye disease, with potential to uniquely address both dry eye and allergic conjunctivitis. Strategic collaboration with AbbVie could bring significant financial milestones and commercial strength.
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Unusually active option classes on open December 16th
Unusual total active option classes on open include: Aldeyra (ALDX), Rezolve AI Ltd (RZLV), B Riley Financial (RILY), Annaly Capital (NLY), Enovix (ENVX), Petrobras (PBR), Canopy Growth (CGC), BP (BP)...
Aldeyra Therapeutics Transcript: Study Update
The FDA extended the PDUFA date for reproxalap's NDA after requesting a field trial CSR, despite prior agreement to omit it. The review is nearly complete, and labeling discussions are underway, with a decision expected by February 2026. The AbbVie partnership terms remain unchanged.
Aldeyra announces PDUFA extension for Reproxalap
The company states: “Aldeyra (ALDX) Therapeutics announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application for the
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...
Aldeyra Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
A major regulatory decision for Reproxalap in dry eye disease is expected in December, with a lucrative AbbVie partnership pending approval. The drug’s rapid onset and anti-redness features set it apart, and late-stage data support expansion into allergic conjunctivitis.
Aldeyra Therapeutics Transcript: Jefferies London Healthcare Conference 2025
A major FDA decision for a dry eye therapy is expected in December, with strong clinical data and commercial plans in place, including a significant partnership with AbbVie. The pipeline includes late-stage and preclinical programs targeting ocular, dermatological, and neurological diseases.
Aldeyra Therapeutics Transcript: R&D Day 2025
RASP modulation platform is expanding into CNS and immune-mediated diseases, with ADX-248 showing strong preclinical efficacy and reproxalap advancing toward potential FDA approval. Financial runway extends into 2027, and key regulatory and manufacturing milestones have been met.
Aldeyra expands RASP platform
Aldeyra (ALDX) announced at a research and development webcast the expansion of the RASP platform to include programs in central nervous system diseases associated with inflammation, and provided upda...
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-medi...